DNMT3A mutation

There are 4 papers on DNMT3A mutation in aging research: 2 observational studies in people. The newest story, Oct 14, 2026: “TET2 loss alters DNA copying during drug treatment in cells”.

Biomarker

4 papers study it38 more mention it

4 new papers in 30 daysSee all 42 papers on DNMT3A mutation

  • Humans2
  • In silico1

Funding

7 grants since 2019

National Heart, Lung, and Blood Institute$4.2MNational Cancer Institute$842KNational Institute of Diabetes and Digestive and Kidney Diseases$1.7M

Latest

Dec 2025: 1Jan 2026: 1Feb 2026: 1Mar 2026: 3Apr 2026: 1May 2026: 0Jun 2026: 0Jul 2026: 4Aug 2026: 1Sep 2026: 5Oct 2026: 1Nov 2026: 321 papers in 12 months
Nature Communications

TET2 loss alters DNA copying during drug treatment in cells

Lab experiments showed that Olaparib treatment lengthened copied DNA tracts, increased DNA breaks and heightened drug sensitivity in cells lacking TET2, but not DNMT3A.Lab experiments showed that Olaparib treatment lengthened copied DNA tracts, increased DNA breaks and heightened drug sensitivity in cells lacking TET2, but not DNMT3A.

Human cell studyTET2
International Journal of Molecular Sciences

Donor TET2 variant linked to lower stem cell transplant survival

Recipients whose donors carried a TET2 Leu1721Trp variant lived a median of 14.3 months compared with 50.8 months for those with wild-type donors.Recipients whose donors carried a TET2 Leu1721Trp variant lived a median of 14.3 months compared with 50.8 months for those with wild-type donors.

Case series of 20 peopleMechanisms

See all 42 papers on DNMT3A mutation